Potent Inhibition of Arterial Thrombosis and Venous Thrombogenesis Subject to Adequate Hemostasis via Disrupting β3/Src Interaction in Platelets
Thrombosis and Haemostasis · 01.09.2026 · 126 (09) · 930-947
DOI: 10.1055/a-2706-9879 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.09.2026. Verfasst von Jiayi Chen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Collabor…. Hauptthemen laut MEDLINE: Blood Platelets, Hemostasis, Venous Thrombosis, Thrombosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality, National Key R&D Program of China.
Abstract (Originalsprache)
Antiplatelet and anticoagulation are the cornerstones for arterial and venous thrombosis, respectively; however, hemorrhage remains a significant clinical challenge. Platelets are crucial for arterial thrombosis and contribute to venous thrombosis. Integrin β3 mediates outside-in signaling, which is critical for thrombosis, while inside-out signaling maintains hemostasis. Targeting the β3/Src interactions to selectively inhibit outside-in signaling offers a promising antithrombotic strategy without compromising hemostasis. To develop more potent small molecules that selectively disrupt the β3/Src interaction, thereby inhibiting arterial and venous thrombogenesis without increasing bleeding risk. Building on the previously identified compound DCDBS84, we developed the structurally modified small molecules C109 and C116, with enhanced affinity for the Src SH3 domain. Their antithrombotic effects on both arterial and venous thrombosis were systematically evaluated through in vitro and in vivo studies. The impact on hemostatic function was assessed using a tail-bleeding model. Additionally, the drug developability of C109 was assessed via pharmacokinetic (PK) and metabolite analysis. C109 and C116 exhibited superior efficacy in disrupting the β3/Src interaction. In vitro and in vivo studies demonstrated that C109 and C116 effectively suppress thrombosis at levels comparable to high doses of the αIIbβ3 antagonist integrilin, without elevating bleeding risk. In the Stenosis Model, C109 and C116 significantly reduced venous thrombogenesis by suppressing platelet activation and neutrophil extracellular trap formation. Additionally, C109 displayed favorable PK properties and robust metabolic stability. These findings identify promising small molecules that inhibit thrombosis while maintaining hemostasis, providing new avenues for safer and more effective clinical management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Collaborative Innovation Center of Hematology, Ruijin Hospital, Shanghai Jiao…
- Research Center for Experimental Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Guangdong, China.
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
- Institute for Development and Regenerative Cardiovascular Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
ORCID-Profile: Jianhua Mao
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- National Key R&D Program of China
Zitieren
APA
Chen, J., Liu, S., Shen, Y., Xiong, H., Chen, C., Xiao, B., Wang, Y., Jin, L., Yu, W., Xu, D., Ruan, Z., Liu, J., Yang, Y., Mei, L., Hua, L., Luo, C., Zhou, B., Wang, K., Xi, X., & Mao, J. (2026). Potent Inhibition of Arterial Thrombosis and Venous Thrombogenesis Subject to Adequate Hemostasis via Disrupting β3/Src Interaction in Platelets. Thrombosis and Haemostasis, 126(09), 930-947. https://doi.org/10.1055/a-2706-9879
Vancouver
Chen J, Liu S, Shen Y, Xiong H, Chen C, Xiao B, et al. Potent Inhibition of Arterial Thrombosis and Venous Thrombogenesis Subject to Adequate Hemostasis via Disrupting β3/Src Interaction in Platelets. Thrombosis and Haemostasis. 2026;126(09):930-947. doi:10.1055/a-2706-9879
BibTeX
@article{Chen2026,
author = {Chen, Jiayi and Liu, Shuang and Shen, Yan and Xiong, Huan and Chen, Chao and Xiao, Bing and Wang, Yun and Jin, Lu and Yu, Wanlin and Xu, Dounan and Ruan, Zheng and Liu, Jingqiu and Yang, Yaxi and Mei, Lianghe and Hua, Li and Luo, Cheng and Zhou, Bing and Wang, Kankan and Xi, Xiaodong and Mao, Jianhua},
title = {Potent Inhibition of Arterial Thrombosis and Venous Thrombogenesis Subject to Adequate Hemostasis via Disrupting β3/Src Interaction in Platelets},
journal = {Thrombosis and Haemostasis},
year = {2026},
volume = {126},
number = {09},
pages = {930--947},
doi = {10.1055/a-2706-9879}
}
EUVIMED